News from South San Francisco
Stay current with all the latest and breaking news about South San Francisco, compare headlines and perspectives between news sources on stories happening today. In total, 40 stories have been published about South San Francisco which Ground News has aggregated in the past 3 months.
Weather
16°C
16°CThursday
11° | 17°C
11° | 17°CFriday
11° | 16°C
11° | 16°CSaturday
9° | 12°C
9° | 12°CSunday9° | 12°C
9° | 12°CMonday9° | 13°C
9° | 13°CTuesday10° | 15°C
10° | 15°CLocal News Publishers
Suggest a source
Looking for a source we don't already have? Suggest one here.Top South San Francisco News
Latest News Stories
Science · South San FranciscoNew 330,000-square-foot high-tech building will host science and technology workers in the West Coast's fastest growing life sciences market SAN FRANCISCO, April 16, 2024 /PRNewswire/ -- McCarthy Building Companies, Inc., in collaboration with IQHQ, VFR, Perkins&Will and design-build trade partners, raised the final beam today on Spur Phase One located at 580 Dubuque Avenue in South San Francisco. The Class A, high-tech life science all-electric…See the Story
McCarthy and IQHQ Mark Milestone Topping Out on Spur Phase One in South San Francisco
100% Center coverage: 1 sources
Wages · South San FranciscoMichael Siluk/UCG/Universal Images Group via Getty ImagesA California restaurant owner says he plans to raise his wages after the minimum for fast-food workers shot up to $20.Other businesses in the state will likely have to pay workers more to compete for labor.The owner said the new minimum wage compounds years of difficulties for restaurants in California.The owner of a restaurant in California says he'll "absolutely" have to raise his wages …See the Story
A California restaurant owner says he'll 'absolutely' have to put up wages to compete with fast-food chains now paying $20 an hour
100% Left coverage: 1 sources
South San Francisco · South San FranciscoSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2024 (the "Grant Date"), ORIC granted a total of 84,800 non-qualified stock options and 14,400 restricted stock units to two new non-executive employees who began their employm…See the Story
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - ORIC Pharmaceuticals (NASDAQ:ORIC)
67% Left coverage: 3 sources
South San Francisco · South San FranciscoSOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical study of aficamten in patients with hypertrophic cardiomyopathy (HCM), at the 73rd Annual American College of Cardiology (ACC) Scientific Session taking place fr…See the Story
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session - Cytokinetics (NASDAQ:CYTK)
100% Center coverage: 1 sources
South San Francisco · South San FranciscoSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in…See the Story
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
100% Left coverage: 1 sources
South San Francisco · South San FranciscoThe experimental biotech startup Verve Therapeutics has paused the first phase of a buzzy human gene-editing trial due to strange side effects in a patient, according to a report from Bloomberg. The trial in question — dubbed the "Heart-1" trial — is the company's attempt to use gene editing to reduce heart-attack-causing cholesterol in patients with familial hypercholesterolemia, a passed-down genetic disorder that causes buildups of LDL choles…See the Story
Gene Editing Experiment Halted as Patient Gets Weird Side Effects
100% Left coverage: 1 sources
